Citations

Clear

194 citation(s) found for "Borges, VF".

Abstract PS9-08: The psychosocial impact of caregiving on partners of young women with breast cancer in treatment
Gray, Tamryn F. , Borstelmann, Nancy A. , Rosenberg, Shoshana M. , Gelber, Shari , Meyer, Meghan E., Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Maramaldi, Peter , Borges, Virginia F. , Cadet, Tamara , Partridge, Ann H.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PS9-08-PS9-08

10.1158/1538-7445.sabcs20-ps9-08 Get It

Abstract BackgroundCancer diagnosis and early treatment may have wide-ranging consequences for a woman’spartner (ie. spouse or significant other). In general, younger caregivers have been found to havegreater unmet needs and higher levels of distress compared to those who are older. To date,there is little known about the unmet needs and experiences of partners who care for youngwomen with breast cancer during active treatment.Trial Design: Cross-sectional survey of partners of young women with breast cancer.Eligibility Criteria: The current analysis focuses on a subset of respondent partners of womenwith breast cancer participating in the Young Womens Breast Cancer Study (NCT01468246)who met the following criteria: diagnosed at age < 40 years; time since diagnosis <12 months;and/or Stage IV disease (at diagnosis or in metastatic setting); and/or local recurrent disease< 12 months.Specific Aims: To explore the experience of partners of women in active treatment or havingvery recently completed treatment for breast cancer.Statistical Methods: We employed descriptive statistics to present sample characteristics,including means or medians for continuous variables and proportions for categorical variables.We assessed partners’ responses re: sociodemographics, perceived social support (MOS-Social Support Survey, Cancer Perceived Agents of Social Support), quality of life (QOL)(Caregiver QOL Index-Cancer), coping (Brief COPE), perceived financial security, perceivedparenting concerns (Parenting Concerns Questionnaire), anxiety and depression symptoms(Hospital Anxiety and Depression Scale), sexual satisfaction (Global Measure of SexualSatisfaction), posttraumatic growth (Posttraumatic Growth Inventory-Short Form), and an open-ended question to explore their experiences and needs.Accrual: 25 participants were included.Results: All partners were male (25/25; 100%), and most were white (n=23/25; 92%), workingfull-time (n=21/25; 91%); and college educated (n=19/25; 86%). Eighteen partners (n=18/25;72%) were parenting children <18 years old and 40% (n=10/25) were partnered with womenwith Stage 4 breast cancer. At the time of the survey, the median age of partners was 44 years(range, 28-69) and of patients was 38 years (range, 25-40). Many partners (57%) reportedsymptoms of anxiety (>8 on the HADS anxiety subscale), fewer (22%) were categorized ashaving symptoms of depression (>8 on the HADS depression subscale). Additionally, 39%reported not being sexually active; 41% reported maladaptive coping; 30% reported financialstrain;30% reported relationship strain. Reported caregiver QOL ranged from 22-116, with amean score of 52.5 (SD, 23.9), similar to population norms, with higher scores indicating lowerquality of life. Parenting concerns scores were generally low indicating less concern, with arange of 12-35, and mean of 20.5 (SD, 7.6). Post-traumatic growth ranged from 4-33, with amean score of 20.7 (SD, 7.4), with higher scores indicating greater personal growthexperienced. 44% (11/25) responded to the open-ended experiences and needs question.Common responses included feeling a lack of support, need for tailored and titrated information,and desire to connect with other men who faced similar experiences. Partners also reportedtheir struggles with uncertainty about the future. Discussion: A subset of partners of young women in active treatment for breast cancerexpressed concerns related to relationship strain, sexuality, need for support, and finances.Future work designed to meet the needs of partners of breast cancer patients includinginformational and psychosocial supports may benefit them and the patients as they manage theprocess of ongoing treatment and challenges about the future. Citation Format: Tamryn F Gray, Nancy Borstelmann, Shoshana Rosenberg, Shari Gelber, Meghan E Meyer, Kathryn J. Ruddy, Lidia Schapira, Steven Come, Virginia Borges, Tamara Cadet, Peter Maramaldi, Ann H. Partridge. The psychosocial impact of caregiving on partners of young women with breast cancer in treatment [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS9-08.
Abstract PD2-08: Endocrine therapy non-persistence and recurrence in young women with early stage breast cancer
Rosenberg, Shoshana M. , Poorvu, Philip D. , Ruddy, Kathryn J. , Schapira, Lidia , Peppercorn, Jeffrey , Come, Steven E. , Zheng, Yue , Gaither, Rachel , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PD2-08-PD2-08

10.1158/1538-7445.sabcs20-pd2-08 Get It

Abstract Background: Young age at diagnosis is an independent risk factor for recurrence and death from breast cancer (BC), with the greatest impact of young age demonstrated in hormone receptor positive (HR+) disease. Younger women are less likely to be adherent to endocrine therapy (ET), which may contribute to disparate outcomes. Methods: As part of a prospective cohort that enrolled women with BC diagnosed at age ≤40 between 2006-2016, we identified women with HR+, Stage I-III BC. Serial surveys with items assessing socio-demographic and treatment information including medication use are administered 1-2 times per year. Medical record review was used to ascertain stage and HR status and to confirm recurrent disease (locoregional, distant, or new primary breast cancer). Women who initiated ET but discontinued it <5-years post-diagnosis without resumption were classified as non-persistent. Univariable and multivariable regression models were fit to identify predictors of non-persistence and recurrence.Results: Among 607 women who initiated ET (median age at diagnosis: 36, range:17-40; 38%, 45%, 17% were Stage 1, 2, and 3, respectively).16% (99/607) were non-persistent, of whom 30% (30/99) discontinued ET ≤2 years post-diagnosis and over half had discontinued (54%, 54/99) by 3 years. In multivariable regression, those who were younger at diagnosis (age ≤30 vs. 36-40: OR: 3.39, 95% CI: 1.84-6.24; age 31-36 vs. 36-40: OR: 2.81 95% CI: 1.70-4.64) were more likely to discontinue ET while those with a higher stage at diagnosis were less likely to discontinue ET (Stage 2 vs. 1: OR: 0.46, 95% CI: 0.29-0.74; Stage 3 vs 1: OR: 0.32, 95% CI: 0.15-0.68). At a median follow-up time from diagnosis of 7.8 years (range 1-13 years), 15% of women (88/607) recurred or developed a new primary BC at a median time from diagnosis of 3.5 years (range 1-12 years). Of these, 66% (58/88) were distant recurrences, 32% (28/88) loco-regional, and 2% (2/88) new primary BCs. Rates of recurrence were higher among women who were persistent (81/508, 16%) vs. non-persistent (7/99, 7%, p=0.02). In multivariable regression, those who were non-persistent were less likely to recur (OR: 0.43, 95% CI: 0.19-0.98) while those with a higher stage were more likely to recur (Stage 3 vs. 1: OR: 2.36, 95% CI: 1.03-5.41). Sociodemographic, patient, and other treatment factors did not predict recurrence. Conclusions: Approximately 16% of young women with HR+ BC stop ET earlier than indicated, however non-persistence was not a risk factor for BC recurrence a median of 8 years following diagnosis in our cohort. Importantly, women with higher risk disease who are likely to benefit most from adherence to ET were less likely to discontinue treatment. Extended follow-up will further inform the impact of non-persistence on the incidence of late recurrences for which women with HR+ BC are at increased risk. Citation Format: Shoshana M Rosenberg, Yue Zheng, Philip Poorvu, Kathryn Ruddy, Rachel Gaither, Rulla Tamimi, Lidia Schapira, Jeffrey Peppercorn, Steven Come, Virginia Borges, Ann Partridge. Endocrine therapy non-persistence and recurrence in young women with early stage breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD2-08.
Impact of the COVID-19 Pandemic on Maternal Anxiety in Brazil
Nomura, Roseli Mieko Yamamoto , Tavares, Isabela de Paula , Ubinha, Ana Carla Franco , Opperman, Maria Lúcia, Brock, M. , Trapani, Alberto , Damásio, Lia Cruz Vaz da Costa , Reis, Nadia Stella Viegas , Borges, Vera Therezinha Medeiros , Araújo, Ana Cristina Pinheiro Fernandes de , COVID-19, BrAPS-COVID Brazilian Anxiety during Pregnancy Study Group in, Nomura, Roseli , Opperman, Maria Lucia , Trapani, Alberto , Damasio, Lia , Zaconeta, Alberto , Ruano, Rodrigo , Brock, Marianna Facchinetti , Borges, Vera , Costa, Maria Laura , Ruano, Rodrigo , COVID-19, BrAPS-COVID Brazilian Anxiety during Pregnancy Study Group in

Mayo Clinic

Journal of Clinical Medicine | February 7, 2021 | Volume: 10 | Issue: 4 | Pages: 620

10.3390/jcm10040620 | PMID 33562012 Get It

Background: The coronavirus disease 2019 (COVID-19) pandemic may have an effect on maternal anxiety and influence postpartum experience. Objective: To study the prevalence of maternal anxiety in late pregnancy in the context of the COVID-19 outbreak in Brazil and to analyze its association with maternal knowledge and concerns about the pandemic. Methods: This was a national multicenter cross-sectional study performed in 10 different public university hospitals, between 1 June and 31 August 2020, in Brazil. The inclusion criteria were: maternal age more than 18 years; gestational age more than 36 weeks at childbirth; single alive newborn without malformations; and absence of mental disorders. We applied a structured questionnaire to explore the knowledge and concerns about COVID-19. Maternal anxiety was assessed using the Beck Anxiety Inventory (BAI). Results: Of the 1662 women interviewed, the BAI score in late pregnancy indicated that 13.9% presented moderate and 9.6% severe maternal anxiety. Moderate or severe maternal anxiety was independently associated with the fear of being unaccompanied at childbirth (aOR1.12, 95% CI 1.10–1.35), and independent protective factors were confidence in knowing how to protect oneself from COVID-19 (aOR0.89, 95% CI 0.82–0.97) and how to safely breastfeed (aOR0.89, 95% CI 0.83–0.95). Conclusion: The COVID-19 pandemic has a significant impact on maternal anxiety.
Senolytic Combination of Dasatinib and Quercetin Alleviates Intestinal Senescence and Inflammation and Modulates the Gut Microbiome in Aged Mice
Saccon, Tatiana D. , Nagpal, Ravinder , Yadav, Hariom , Cavalcante, Marcelo Borges , Nunes, Allancer Divino de Carvalho, Schneider, Augusto , Gesing, Adam , Yousefzadeh, Matthew J. , Kirkland, James L. , Niedernhofer, Laura J. , Saccon, Tatiana Dandolini , Masternak, Michal M , Niedernhofer, Laura J , Hughes, Brian, Tchkonia, Tamar , Robbins, Paul D.

Mayo Clinic

The Journals of Gerontology: Series A | January 10, 2021 | Volume: 76 | Issue: 11 | Pages: 1895-1905

10.1093/gerona/glab002 | PMID 33406219 Get It

Abstract Cellular senescence contributes to age-related disorders including physical dysfunction, disabilities, and mortality caused by tissue inflammation and damage. Senescent cells accumulate in multiple tissues with aging and at etiological sites of multiple chronic disorders. The senolytic drug combination, Dasatinib plus Quercetin (D+Q), is known to reduce senescent cell abundance in aged mice. However, the effects of long-term D+Q treatment on intestinal senescent cell and inflammatory burden and microbiome composition in aged mice remain unknown. Here, we examine the effect of D+Q on senescence (p16Ink4a and p21Cip1) and inflammation (Cxcl1, Il1β, Il6, Mcp1, and Tnfα) markers in small (ileum) and large (caecum and colon) intestine in aged mice (n = 10) compared to age-matched placebo-treated mice (n = 10). Additionally, we examine microbial composition along the intestinal tract in these mice. D+Q-treated mice show significantly lower senescent cell (p16 and p21 expression) and inflammatory (Cxcl1, Il1β, Il6, Mcp1, and Tnfα expression) burden in small and large intestine compared with control mice. Further, we find specific microbial signatures in ileal, cecal, colonic, and fecal regions that are distinctly modulated by D+Q, with modulation being most prominent in small intestine. Further analyses reveal specific correlation of senescence and inflammation markers with specific microbial signatures. Together, these data demonstrate that the senolytic treatment reduces intestinal senescence and inflammation while altering specific microbiota signatures and suggest that the optimized senolytic regimens might improve health via reducing intestinal senescence, inflammation, and microbial dysbiosis in older subjects.
Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer
Kim, Hee Jeong , Dominici, Laura S. , Rosenberg, Shoshana M. , Pak, Linda M. , Poorvu, Philip D. , Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Peppercorn, Jeffrey , Vardeh, Hilde, Collins, Laura C. , Gaither, Rachel , King, Tari A. , Zheng, Yue , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Partridge, Ann H.

Mayo Clinic

Annals of Surgery | December 25, 2020 | Volume: 276 | Issue: 1 | Pages: 173-179

10.1097/sla.0000000000004296 | PMID 33378304 Get It

Objective: We aimed to investigate eligibility for breast conserving surgery (BCS) pre- and post-neoadjuvant systemic therapy (NST), and trends in the surgical treatment of young breast cancer patients. Background: Young women with breast cancer are more likely to present with larger tumors and aggressive phenotypes, and may benefit from NST. Little is known about how response to NST influences surgical decisions in young women. Methods: The Young Women's Breast Cancer Study, a multicenter prospective cohort of women diagnosed with breast cancer at age ≤40, enrolled 1302 patients from 2006 to 2016. Disease characteristics, surgical recommendations, and reasons for choosing mastectomy among BCS-eligible patients were obtained through the medical record. Trends in use of NST, rate of clinical and pathologic complete response, and surgery were also assessed. Results: Of 1117 women with unilateral stage I-III breast cancer, 315 (28%) received NST. Pre-NST, 26% were BCS eligible, 17% were borderline eligible, and 55% were ineligible. After NST, BCS eligibility increased from 26% to 42% (P < 0.0001). Among BCS-eligible patients after NST (n = 133), 41% chose mastectomy with reasons being patient preference (53%), BRCA or TP53 mutation (35%), and family history (5%). From 2006 to 2016, the rates of NST (P = 0.0012), clinical complete response (P < 0.0001), and bilateral mastectomy (P < 0.0001) increased, but the rate of BCS did not increase (P = 0.34). Conclusion: While the proportion of young women eligible for BCS increased after NST, many patients chose mastectomy, suggesting that surgical decisions are often driven by factors beyond extent of disease and treatment response.
Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer
Poorvu, Philip D. , Gelber, Shari , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Lambertini, Matteo , Rosenberg, Shoshana M. , Ruddy, Kathryn J , Lambertini, Matteo , Partridge, Ann H , Zheng, Yue , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Cancer | December 1, 2020 | Volume: 127 | Issue: 7 | Pages: 1021-1028

10.1002/cncr.33342 | PMID 33259061 Get It

BackgroundMany young women with newly diagnosed breast cancer are interested in future pregnancies. Prospective data regarding fertility interest and reproductive patterns after diagnosis are needed to counsel patients.MethodsThe Young Women's Breast Cancer Study is a multicenter, prospective cohort of women who were diagnosed with breast cancer at age ≤40 years between 2006 and 2016. Women complete surveys at baseline, every 6 months for 3 years, then annually. Here, the authors describe fertility interest and pregnancies within 5 years of diagnosis for women with stage 0 through III breast cancer.ResultsOf 1026 eligible participants, 368 (36%) reported interest in future biologic children at least once within 5 years after diagnosis, including 16% at 5 years after diagnosis. Among 130 women who attempted to become pregnant, 90 (69.2%) conceived; and, among 896 women who did not attempt to conceive, 18 (2.0%) became pregnant, with a total of 152 pregnancies resulting in 91 live births. Factors associated with pregnancy included younger versus older age at diagnosis (aged ≤30 vs 36‐40 years: odds ratio [OR], 6.63; 95% CI, 3.18‐13.83; P < .0001; aged 31‐35 vs 36‐40 years: OR, 5.86; 95% CI, 3.37‐10.17; P < .0001) and being nulliparous versus parous (OR, 2.66; 95% CI, 1.56‐4.53; P = .001). The receipt of endocrine therapy versus no endocrine therapy (OR, 0.35; 95% CI, 0.20‐0.59; P = .001) was inversely associated with pregnancy.ConclusionsMany women remain interested in future fertility in the 4 years after a breast cancer diagnosis, indicating that longitudinal fertility discussions are needed. Although a minority of those interested in having children attempted to become pregnant in the first 5 years, most who attempted to conceive did so and had live births.
500 P2RX7 agonist treatment boosts the ability of IL-12-activated CD8+ T cells to infiltrate and control murine melanoma
Wanhainen, Kelsey M. , Jameson, Stephen C. , Silva, Henrique Borges da

Mayo Clinic

Regular and young investigator award abstracts | November 9, 2020 | Volume: No volume available | Issue: No issue available | Pages: A307.2-A308

10.1136/jitc-2020-sitc2020.0500 Get It

Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health
Borstelmann, Nancy A. , Rosenberg, Shoshana M. , Gelber, Shari , Zheng, Yue , Meyer, M. M.M.M.D.E., Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Cadet, Tamara , Maramaldi, Peter , Rosenberg, Shoshana , Cadet, Tamara , Maramaldi, Peter , Partridge, Ann H , Zheng, Yue , Meyer, Meghan E., Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Journal of Psychosocial Oncology | October 1, 2020 | Volume: 38 | Issue: 6 | Pages: 670-686

10.1080/07347332.2020.1823546 | PMID 33000705 Get It

Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors
Rosenberg, Shoshana M. , Dominici, Laura S. , Gelber, Shari , Poorvu, Philip D. , Ruddy, Kathryn J. , Wong, Julia S., Schapira, Lidia , Come, Steven E. , Peppercorn, Jeffrey , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

JAMA Surgery | September 16, 2020 | Volume: 155 | Issue: 11 | Pages: 1035

10.1001/jamasurg.2020.3325 | PMID 32936216 Get It

Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Haddad, Tufia C. , Stringer-Reasor, Erica , Chien, A. Jo , Borges, Virginia, Nanda, Rita , Albain, Kathy S. , Müller, Aixa , Kemmer, Kathleen, Clark, Amy S. , Perlmutter, Jane , Melisko, Michelle , Schwab, Richard B. , Wilson, Amy , Singhrao, Ruby , Asare, Smita , Veer, Laura J. van’t , Sanil, Ashish, Berry, Donald A. , Pusztai, Lajos , Han, Hyo S , Yau, Christina , Wolf, Denise M. , Wallace, Anne M. , Shatsky, Rebecca , Helsten, Teresa L. , Boughey, Judy C. , Falkson, Carla I. , Mukhtar, Rita A. , Elias, Anthony , Yee, Douglas , Kalinsky, Kevin M. , Isaacs, Claudine , Thomas, Alexandra , Hylton, Nola M. , Symmans, W. Fraser , Rugo, Hope S. , DeMichele, Angela , Esserman, Laura J.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT011-CT011

10.1158/1538-7445.am2020-ct011 Get It

Abstract Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint risk to evaluate novel agents as neoadjuvant therapy for breast cancer. The primary endpoint is pathologic complete response (pCR, ypT0/is ypN0)). DNA repair deficiency in cancer cells can lead to immunogenic neoantigens, activation of the STING pathway, and PARP inhibition can also upregulate PD-L1 expression. Based on these rationales we tested the combination of durvalumab (anti-PDL1), olaparib (PARP inhibitor) and paclitaxel in I-SPY2. Methods: Women with tumors ≥ 2.5 cm were eligible for screening. Only HER2 negative (HER2-) patients were eligible for this treatment, hormone receptor positive (HR+) patients had to have MammaPrint high molecular profile. Treatment included durvalumab 1500 mg every 4 weeks x 3, olaparib 100 mg twice daily through weeks 1-11 concurrent with paclitaxel 80 mg/m2 weekly x 12 (DOP) followed by doxorubicin/cyclophosphamide (AC) x 4. The control arm was weekly paclitaxel x 12 followed by AC x 4. All patients undergo serial MRI imaging and imaging response at 3 & 12 weeks combined with accumulating pCR data are used to estimate, and continuously update, predicted pCR rate for the trial arm. Regimens “graduation with success” when the Bayesian predictive probability of success in a 300-patient phase 3 neoadjuvant trial in the appropriate biomarker groups reaches &gt; 85%. Results: A total of 73 patients received DOP treatment including 21 HR- tumors (i.e. triple-negative breast cancer, TNBC) and 52 HR+ tumors between May 2018 - June 2019. The control group included 299 patients with HER2- tumors. The DOP arm graduated in June 2019, 13 months after enrollment had started, for all HER2- negative and the HR+/HER2- cohorts with &gt; 0.85% predictive probabilities of success. 72 patient completed surgery and evaluable for pCR, the final predicted probabilities of success in a future phase III trial to demonstrate higher pCR rate with DOP compared to control are 81% for all HER2- cancers (estimated pCR rate 37%), 80% for TNBC (estimated pCR rate 47%) and 74.5% for HR+/HER2- patients (estimated pCR rate 28%). Association between pCR and germline BRCA status and immune gene expression including PDL1 will be presented at the meeting. No unexpected toxicities were seen, but 10 patients (14%) had possibly immune or olaparib related grade 2/3 AEs (3 pneumonitis, 2 adrenal insufficiency, 1 colitis, 1 pancreatitis, 2 elevated LFT, 1 skin toxicity, 2 hypothyroidism, 1 hyperthyroidism, 1 esophagitis). Conclusion: I-SPY2 demonstrated a significant improvement in pCR with durvalumab and olaparib included with paclitaxel compared to chemotherapy alone in women with stage II/III high-risk, HER2-negative breast cancer, improvement was seen in both the HR+ and TNBC subsets. Citation Format: Lajos Pusztai, Hyo S. Han, Christina Yau, Denise Wolf, Anne M. Wallace, Rebecca Shatsky, Teresa Helsten, Judy C. Boughey, Tufia Haddad, Erica Stringer-Reasor, Carla Falkson, A. Jo Chien, Rita Mukhtar, Anthony Elias, Borges Virginia, Rita Nanda, Douglas Yee, Kevin Kalinsky, Kathy S. Albain, Aixa Soyano Muller, Kathleen Kemmer, Amy S. Clark, Claudine Isaacs, Alexandra Thomas, Nola Hylton, W. Fraser Symmans, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard Schwab, Amy Wilson, Amy Wilson, Ruby Singhrao, Smita Asare, Laura J. van't Veer, Angela M. DeMichele, Ashish Sanil, Donald A. Berry, Laura J. Esserman, Trial Consortium I-SPY 2. Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT011.